Abstract:This working paper is hosted by The Berkeley Electronic Press (bepress) and may not be commercially reproduced without the permission of the copyright holder. Summary. Randomized clinical trials are a powerful tool for investigating causal treatment effects, but in human trials there are oftentimes problems of noncompliance which standard analyses, such as the intention-to-treat or as-treated analysis, either ignore or incorporate in such a way that the resulting estimand is no longer a causal effect. One alternative to these analyses is the complier average causal effect (CACE) which estimates the average causal treatment effect among a subpopulation that would comply under any treatment assigned. We focus on the setting of a randomized clinical trial with crossover treatment noncompliance (e.g., control subjects could receive the intervention and intervention subjects could receive the control) and outcome nonresponse. In this article, we develop estimators for the CACE using multiple imputation methods, which have been successfully applied to a wide variety of missing data problems, but have not yet been applied to the potential outcomes setting of causal inference. Using simulated data we investigate the finite sample properties of these estimators as well as of competing procedures in a simple setting. Finally we illustrate our methods using a real randomized encouragement design study on the effectiveness of the influenza vaccine. 1. Introduction The focus of empirical studies in medicine is often to estimate the causal effect of treatments, where randomized clinical trials are considered the most acceptable tool for investigating these causal relationships. But in trials involving human subjects there are oftentimes problems of patient noncompliance, where the patient does not adhere to the treatment assigned. In addition, there is also the problem of nonignorable missing data, where the missing-data mechanism may depend on unobserved data. Standard methods and analyses either ignore these complications, which can lead to biased estimates of causal treatment effect, or account for them in such a way that the resulting estimand can no longer be considered a causal effect of treatment. A statistical framework for causal inference that deals with the issue of noncompliance is based on potential outcomes and was first introduced by Neyman (1923) for randomized studies and later developed by Rubin (1974, 1978) for nonrandomized studies and other forms of inference. Rubin's approach, sometimes referred to as the Ru-bin Causal Model (Holland, 1986), provides a framework for defining the parameters of interest and correctly attributing the …

Estimands in clinical trials of complex disease processes

Translating questions to estimands in randomized clinical trials with intercurrent events

Defining estimands using a mix of strategies to handle intercurrent events in clinical trials

Conditional and Unconditional Treatment Effects in Randomized Clinical Trials: Estimands, Estimation, and Interpretation

Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice

Estimating hypothetical estimands with causal inference and missing data estimators in a diabetes trial

Defining estimands in clinical trials: A unified procedure

Time‐to‐event estimands and loss to follow‐up in oncology in light of the estimands guidance

Time-to-event estimands and loss to follow-up in oncology in light of the estimands framework

Estimands in Hematologic Oncology Trials

Series 2-19-2009 Multiple Imputation Methods for Treatment Noncompliance and Nonresponse in Randomized Clinical Trials

Estimands and Cumulative Incidence Function Regression in Clinical Trials: Some New Results on Interpretability and Robustness

Implementation of tripartite estimands using adherence causal estimators under the causal inference framework

Adjusting for time-varying treatment switches in randomized clinical trials: the danger of extrapolation and how to avoid it

Estimation methods for estimands using the treatment policy strategy; a simulation study based on the PIONEER 1 Trial

Estimands for clinical endpoints in tuberculosis treatment randomized controlled trials: a retrospective application in a completed trial

Estimands in Real-World Evidence Studies

Tailored guidance to apply the Estimand framework to Trials within Cohorts (TwiCs) studies

Applying the estimands framework to non-inferiority trials: guidance on choice of hypothetical estimands for non-adherence and comparison of estimation methods

What matters most? Different stakeholder perspectives on estimands for an invented case study in COPD

A safety estimand for late phase clinical trials where the analysis period varies over the subjects